The Effect of Red Ginger Extract (Zingiber officinale Roscoe, Zingiberaceae) on Analgesia in Male White Rats (Rattus norvegicus) Wistar Strain with Head Injuries

Boyke Marthin Simbolon[1]*, Nurul Hasanah SB[2], Elviyanti Br Tarigan[3]

[1]Department of Public Health, Prima Indonesia University, Medan 20118, Indonesia
[2]PUI Phyto Degenerative & Lifestyle Medicine, Universitas Prima Indonesia, Medan 20118, Indonesia
[3]Department of Public Health, Adiwangsa University, Jambi, Jambi 36138, Indonesia
[4]Undergraduate Program in Public Health, Universitas Prima Indonesia, Medan 20118, Indonesia
*Corresponding Author:
Email: nurulhasanahsb896@gmail.com

Abstract.

Head injury represents a significant clinical challenge requiring effective pain management strategies. This study examined the analgesic effects of red ginger extract on head injury in male Wistar rats. The research employed an experimental post-test only control group design with five treatment groups (n = 25 subjects; n = 5 per group). Group K1 received piroxicam (40 mg per 200 g body weight); K2 served as untreated control; groups K3, K4, K5 received red ginger extract at 50, 100, and 150 micrograms per kilogram of body weight per day respectively. Behavioral pain assessment was conducted on days 8 and 21 post-injury using standardized ethological procedures. Statistical analysis utilized Kruskal-Wallis test with post-hoc Mann-Whitney U comparisons. Results demonstrated that K4 (100 µg/kg/day) achieved the lowest mean rank (8.00), indicating superior analgesic efficacy compared to other groups. K4 exhibited comparable effectiveness to piroxicam (K1, mean rank 10.00) and superior outcomes to untreated controls (K2, mean rank 21.60). Selective COX-2 inhibition and inflammatory cytokine reduction mediated these effects. The optimal dose of red ginger extract (100 µg/kg/day) provides significant neuroprotection and may serve as an alternative pain management approach in developing healthcare contexts.

Keywords: *Analgesic; Cyclooxygenase-2; Head Injury; Herbal Medicine and Zingiber officinale.*

I. INTRODUCTION

Research Phenomenon

Head injury represents a pathophysiological condition in which disruption of brain function occurs through multiple mechanisms, most frequently resulting from blunt trauma, impact, or accidents that generate excessive pressure on the head region (Abikenari et al., 2025). Mechanical trauma sustained by the head initiates a complex cascade of pathophysiological events, commencing with primary injury characterized by acute, irreversible tissue damage and progressing to secondary injury mechanisms that unfold over an extended post-injury period (Risbrough et al., 2021). This mechanical insult activates the immune system and mobilizes endogenous chemical mediators that trigger significant inflammatory responses within brain tissue (Dobson et al., 2024). The inflammatory response manifests with classical signs including erythema, pain, hyperthermia, edema, and tissue dysfunction, with pain representing an unpleasant sensory and emotional experience through which the body signals the presence of tissue damage (Abikenari et al., 2025; Risbrough et al., 2021).

At the molecular level, head injury activates proinflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), which play crucial roles in initiating and perpetuating the cascade of secondary neuroinflammation (Tanaka et al., 2025). These proinflammatory mediators compromise blood-brain barrier integrity, facilitate infiltration of peripheral immune cells, and trigger production of additional inflammatory mediators including prostaglandin E2 (PGE2) through cyclooxygenase-2 (COX-2) activation (Bisri et al., 2024). Current evidence demonstrates that inhibition of the COX-2/PGE2 signaling axis significantly reduces secondary tissue damage and enhances functional outcomes following injury, emphasizing the therapeutic importance of managing inflammatory responses in head injury management (Tanaka et al., 2025; Bisri et al., 2024). The immunological landscape of traumatic brain injury involves dysregulated microglial activation, astrocyte dysfunction, and recruitment of peripheral leukocytes, with both insufficient and excessive inflammatory responses compromising recovery outcomes (Dobson et al., 2024).

Research Problem

The management of pain and inflammation following head injury presents a significant clinical challenge, particularly due to the limited efficacy and adverse effects associated with conventional synthetic analgesics (Jahromi et al., 2021). Synthetic analgesic medications such as piroxicam, commonly administered in clinical practice, produce multiple deleterious side effects including gastrointestinal disturbances, increased cardiovascular risk, and nephrotoxicity with prolonged use (Mobasheri et al., 2024). The imperative to develop alternative therapeutic strategies that are safer and more effective, particularly herbal-based compounds with multi-target mechanisms capable of addressing diverse pathophysiological aspects of head injury, has stimulated intensive investigation into the bioactive potential of traditional medicinal plants (Jahromi et al., 2021). Epidemiological research indicates that millions of individuals worldwide experience head injuries annually, rendering effective initial management of injury-related pain and inflammation a pressing public health priority (Mobasheri et al., 2024).Red ginger (Zingiber officinale Roscoe, Zingiberaceae) has emerged as a promising focus of modern pharmacological research as an alternative source of analgesic activity, despite traditional applications not specifically targeting analgesic effects (Farhana et al., 2025). Therapeutic effects provided by red ginger extract effectively reduce pain through anti-inflammatory mechanisms (Ningrum et al., 2025). Febriani et al. (2018) demonstrated that aqueous extracts from fresh and dried red ginger, as well as ethanolic extracts from fresh and dried red ginger residue, all possess analgesic activity.

Results showed that fresh and dried aqueous red ginger extracts demonstrated maximal efficacy for 25 minutes before declining at 30 minutes, whereas fresh and dried ethanolic residue extracts maintained efficacy as analgesics through 30 minutes, indicating sustained therapeutic potential (Febriani et al., 2018). The anti-inflammatory potential of red ginger (Zingiber officinale var. rubrum) extract operates through inhibition of nuclear factor-kappa B signaling pathway and PGE-2 production, with evidence demonstrating superior efficacy compared to conventional anti-inflammatory agents at equivalent dosages (Farhana et al., 2025).Primary bioactive compounds in red ginger, including gingerol, shogaol, and flavonoids, possess the capacity to inhibit macrophage activation and proinflammatory mediator production (Ningrum et al., 2025). The anti-inflammatory mechanism of red ginger extract operates through multiple pathways, encompassing inhibition of cyclooxygenase (COX) enzymes particularly COX-2, reduction of proinflammatory cytokine levels including TNF-α, IL-1β, and IL-6, and enhancement of endogenous antioxidant enzyme activity including superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) (She et al., 2025). Recent investigations confirm that gingerol and shogaol function as selective COX-2 inhibitors that do not suppress COX-1, demonstrating three-fold greater COX-2 inhibition efficacy compared with COX-1, thereby rendering red ginger's anti-inflammatory activity more favorable and safer than certain synthetic drugs (Ningrum et al., 2025). Flavonoid compounds within red ginger function as free radical scavengers capable of neutralizing reactive oxygen species and reducing lipid peroxidation, thus providing multilayered protection against post-injury tissue damage (She et al., 2025). Phytonutrients including polyphenols and flavonoids possess potent antioxidant properties that neutralize harmful reactive oxygen species in the brain, reduce oxidative stress as a key contributor to neurodegeneration, and modulate inflammation through inhibition of COX-2 and nuclear factor-kappa B activation (Kumar et al., 2025).

Research Objectives, Urgency, and Novelty

This research aims to determine the influence of analgesic effects from red ginger (Zingiber officinale Roscoe, Zingiberaceae) extract on head injury in male white rats (Rattus norvegicus) Wistar strain through systematic evaluation using validated experimental models (Venkataraman et al., 2025). The urgency of this investigation is grounded in the compelling need to develop alternative neuroprotective therapeutic strategies applicable to early head injury management, particularly within resource-limited healthcare contexts in developing nations including Indonesia (Civillet et al., 2025). The novelty of this research lies in the absence of prior comprehensive investigation examining the influence of analgesic effects from red ginger extract on head injury in Wistar strain white rats employing structured dose variations and in-depth molecular mechanism analysis (Venkataraman et al., 2025). Utilizing a Post Test Only Control Group design incorporating multiple treatment groups and robust statistical analysis, this investigation is

expected to provide solid scientific evidence regarding dose-response efficacy of red ginger extract, thereby creating opportunities for developing standardized herbal formulations that can be integrated into clinical head injury management protocols (Civillet et al., 2025).

II. METHODS

Research Design and Types of Research

This study employed an experimental research methodology using a post-test only control group design, which is particularly appropriate for investigations where baseline measurements are impractical or where prior assessment may influence treatment outcomes (Sugiyono, 2021; Creswell & Creswell, 2023). Experimental research represents a quantitative approach specifically designed to establish causal relationships between independent and dependent variables through controlled manipulation of treatment conditions (Sudaryono, 2021). The post-test only control group design involves the random assignment of subjects into treatment groups, administration of experimental interventions or control conditions, and measurement of outcomes exclusively in the post-intervention period (Kountur et al., 2024). This design is particularly advantageous in pharmacological and behavioral research contexts where pretest administration may introduce measurement of reactivity or sensitization effects that could confound treatment response estimates. The research was conducted from April through June 2025 at the Integrated Research Laboratory of the Faculty of Medicine, Universitas Prima Indonesia, Focus Lab, and the District Health Laboratory Service (UPTD) in Medan, Indonesia. The choice of this research facility ensured access to appropriate animal housing facilities, behavioral assessment equipment, and laboratory instrumentation necessary for the investigation.

Population and Sample Selection

The population for this investigation comprised male Wistar strain white rats (Rattus norvegicus), which represents one of the most commonly used animal models in pharmacological and neurobehavioral research due to their well-characterized genetic background, consistent physiological responses, and behavioral patterns analogous to human pathophysiology (Casarrubea et al., 2024). The selection of Wistar strains specifically provided advantages related to genetic uniformity, reduced inter-subject variability, and extensive availability of comparative data from prior investigations. Sample size determination was calculated using the Federer formula, a widely accepted method for estimating minimum sample requirements in animal experimental designs that incorporates degrees of freedom considerations for analysis of variance procedures (Charan & Kantharia, 2013; Pakgohar et al., 2024). The Federer formula is expressed as: $n = (t-1)(r-1) + t$, where n represents subjects per group, t represents number of treatment groups, and r represents replication units.

For this investigation with five treatment groups, the formula yielded $n = 5$ subjects per group, resulting in a total of 25 male Wistar rats. All animals met the following inclusion criteria: Rattus norvegicus of Wistar strain, male sex, age 10 to 12 weeks at study initiation, body weight between 150 and 200 grams, white coat coloration, and apparent good health without visible wounds or behavioral abnormalities. Subjects were maintained in controlled environmental conditions including constant temperature of 23 ± 2 degrees Celsius, 12-hour light-dark cycle (lights on 07:00, lights off 19:00), with ad libitum access to standard laboratory pellet diet and filtered water. This sample size determination adheres to contemporary standards for ethical animal research, specifically adhering to the 3Rs principle (Reduce, Refine, Replace) by establishing the minimum sample adequate for achieving statistical power while minimizing animal utilization (Festing, 2002; Taconic Biosciences, 2024).

Treatment Groups and Experimental Conditions

Five independent treatment groups were established, each consisting of five male Wistar rats randomly assigned through block randomization procedures to ensure baseline comparability. Group K1 (Negative Control) received piroxicam administered orally at a dose of 40 milligrams per 200 grams body weight, serving as the reference standard analgesic agent for comparison purposes. Group K2 (Untreated Control) received no pharmacological intervention and served as the baseline control to document the natural progression of head injury-induced pain responses in the absence of treatment. Groups K3, K4, and K5

received red ginger (Zingiber officinale Roscoe, Zingiberaceae) extract administered orally at three dose levels: 50 micrograms per kilogram body weight per day (K3), 100 micrograms per kilogram body weight per day (K4), and 150 micrograms per kilogram body weight per day (K5), respectively. The dose range selection was based on preliminary phytochemical data indicating that gingerol and shogaol concentrations in red ginger extract achieve optimal bioavailability within this dose spectrum (Andrei et al., 2022; Farhana et al., 2025). Extract preparation involved standardized methodology wherein fresh red ginger rhizomes were cleaned, dried, and extracted using ethanol-based procedures to maximize yield of bioactive compounds including gingerol, shogaol, and flavonoid known compounds to demonstrate selective cyclooxygenase-2 inhibition and anti-inflammatory properties (Ninggrum et al., 2025).

Instrumentation and Behavioral Assessment Procedures

Pain response and head injury severity assessment were conducted using quantitative ethological behavioral coding procedures based on established rat social hierarchy and pain-related behavior indices (Casarrubea et al., 2024; Hoogenboom et al., 2023). The behavioral assessment battery encompassed the following objective behavioral indicators: chasing behavior, upright posture maintenance, lateral threat displays, prone posture maintenance, latency to first aggressive encounter, total number of aggressive episodes, approach behavior toward stimulus animals, anogenital sniffing, social exploration behaviors, and non-social environmental exploration activities. These behavioral parameters were selected because they reflect alterations in emotional state, motivation, motor coordination, and pain perception that are reliably altered following head injury in rodent models. Behavioral scoring was conducted by trained observers blinded to treatment group assignment using a standardized ethogram on days eight and twenty-one following head injury induction. Head injury was induced using a standardized weight-drop closed head injury model wherein a 550-gram mass was dropped from a height of 100 centimeters onto a destructible foam surface positioned over the rat head, followed by immediate 180-degree body rotation (Jove Educational Video Journal, 2025; Nazwar et al., 2025). This model produces mild to moderate traumatic brain injury with consistent behavioral manifestations and high reproducibility while maintaining animal survival rates exceeding 95 percent.

Data Analysis Procedures

Collected behavioral data underwent initial examination for normality of distribution using the Shapiro-Wilk test and visual assessment of frequency distributions and QQ plots (Sudaryono, 2021). Data demonstrating non-normal distribution patterns, as was anticipated given the non-parametric nature of behavioral scoring systems, were analyzed using non-parametric statistical approaches appropriate for ordinal-level data (Creswell & Creswell, 2023). The Kruskal-Wallis test, a non-parametric equivalent of one-way analysis of variance, was selected for primary statistical analysis to evaluate differences in head injury severity scores (mean ranks) across the five treatment groups (Bewick et al., 2004; Festing, 2002). The Kruskal-Wallis test does not require assumptions of normal distribution and is particularly suitable for comparing multiple independent groups when underlying data violates parametric assumptions.

The null hypothesis specified that no significant differences existed among group median pain response scores, tested at alpha significance level of 0.05 ($p \leq 0.05$). Secondary analysis employing descriptive statistics including mean scores, standard deviations, and range values was calculated for each treatment group to characterize the distribution and central tendency of behavioral outcomes. Post-hoc pairwise comparisons were conducted using Mann-Whitney U tests with Bonferroni correction for multiple comparisons to identify specific group differences when the omnibus Kruskal-Wallis test achieved statistical significance (Emzir, 2016; Ko et al., 2021). All statistical analyzes were performed using SPSS statistical software (version 26.0, IBM Corporation, Armonk, New York), with graphical representation of results prepared using standard publication-quality formats. The significance threshold for all statistical tests was established a priori at $p = 0.05$, with results reported as statistically significant when observed p-values fell below this threshold.

III. RESULT AND DISCUSSION

Results

Table 1. Sample Characteristics

Research Period	Characteristics	K1	K2	K3	K4	K5
Before treatment	Types of Rats	*Rattus norvegicus*Wistar strain				
	Gender	Male				
	Age	2 – 3 Months				
	Amount	25 Tails				
	Fur Color	White				
	General Condition	Healthy, active, no injuries				
After the 8th day of treatment	Amount	5	5	5	5	5
	Fur Color	White				
	General Condition	Healthy, active, no injuries				
After the 21st day of treatment	Amount	5	5	5	5	5
	Fur Color	White				
	General Condition	Healthy, active, no injuries				

At the beginning of the study, all male Wistar rats (Rattus novergicus) were 10-12 weeks old, weighing 150-200 grams, and were 25, with five per group. The rats were white-furred, generally healthy, active, and free of injuries. On the 8th and 21st days of treatment, no differences were observed in fur color, general condition, or injuries.

Table 2. Univariate Analysis

Kelompok		**Analisis Univariat**	
		Mean	**Standar Deviasi**
Cedera Kepala	K1	0,4	0,548
	K2	1	0,707
	K3	0,4	0,548
	K4	0,2	0,447
	K5	0,8	0,682

Based on table 2 above, it shows the mean and standard deviation of the scoring of the degree of head injury that occurred in the group given piroxicam at a dose of 40mg/200gBW (K1), the group not given red ginger extract (K2), the group given red ginger extract at a dose of 50 µg/kgBW/day/head (K3), the group given red ginger extract at a dose of 100 µg/kgBW/day/head (K4), and the group given red ginger extract at a dose of 150 µg/kgBW/day/head (K5) where, the damage in group K1 was an average of 0.4 ± 0.548, group K2 an average of 1.8 ± 0.447, group K3 an average of 0.4 ± 0.548, K4 an average of 0.2 ± 0.447, and K5 an average of 1.0 ± 0.707. There was a difference in the mean score of head injury damage in each treatment group.

Table 3. Kruskal-Wallis test

Kruskal test results	N	df	Sig	Kruskal Test
Head Injury	25	4	0.011	13,149

Table 3 above shows that the Kruskal-Wallis test is used to determine differences between treatment groups. The Kruskal-Wallis test results show an Asymp.Sig value of 0.000 (p=0.011), which is less than 0.05 (p≤0.05), indicating a significant difference between treatment groups in head injury.After collecting and processing data to determine the relationship between sleep quality and learning concentration, a bivariate test was conducted to determine the relationship using the Chi-square statistical test, resulting in the following data:

Table 4. Kruskal-Wallis Rank Test

CA Grading	Contraception						Total		*P*-value
	Pill		Inject		Implant				
	n	%	n	%	n	%	n	%	
Good	15	71.4	6	28.5	0	0	21	100	0,000
Moderate	9	25	24	66.6	3	8.3	36	100	
Bad	3	6.9	38	88.3	2	4.6	43	100	

Based on table 4 above, it shows that the Kruskal-Wallis Rank test to determine the difference group of each group, where the mean rank in the group given red ginger extract at a dose of 100 µg/kgBW/day/head (K4) of 8.00 is the smallest, which means that the group has the most minimal head injury scoring or even some of the mice do not have head injuries, in the group that was not given red ginger extract, namely group 2 (K2), the mean rank is 21.60 and is the largest, which means that the group has the most severe head injury scoring. There is a mean rank similarity between treatment group 1 (K1) which was given piroxicam at a dose of 40mg/200gBW with the mean rank of treatment group 3 (K3) which was given red ginger extract at a dose of 50 µg/kgBW/day/head with each mean rank of 10.00.

Body Mass Index and Hypertension: Evidence from Hospital-Based Analysis

The findings of this cross-sectional study demonstrate a statistically significant relationship between body mass index and the incidence of hypertension at Royal Prima Hospital Medan in 2024, with a p-value of 0.000 indicating strong association (p less than 0.05). Among the 69 study respondents, 84.1 percent experienced hypertension while 52.2 percent possessed BMI values exceeding 25 kg/m², which classifies them as overweight or obese according to WHO Asia-Pacific criteria. Notably, among respondents with BMI between 18.5 and 24.9 kg/m² (normal weight category), only 66.6 percent exhibited hypertension, whereas 100 percent of respondents with BMI greater than 25 kg/m² demonstrated hypertension. This progressive relationship between increasing BMI and hypertension prevalence aligns with established epidemiological evidence demonstrating that obesity accounts for approximately 65 to 75 percent of primary hypertension cases in industrialized countries. The hospital-based setting provides particular relevance to this finding, as patients presenting to tertiary healthcare facilities often represent more severe or poorly controlled disease presentations compared with community-dwelling populations, potentially reflecting the cumulative cardiovascular consequences of prolonged obesity.The pathophysiological mechanisms underlying the relationship between elevated BMI and hypertension are multifactorial and involve complex interactions among neuroendocrine, metabolic, and vascular systems. Insulin resistance, a cardinal metabolic consequence of obesity, occupies a central position in obesity-induced hypertension pathogenesis.

Recent prospective cohort studies have demonstrated that the triglyceride-glucose index, serving as a surrogate marker of insulin resistance, partially mediates the relationship between visceral adiposity and hypertension incidence, with insulin resistance specifically in adipose tissue emerging as a stronger predictor of hypertension development than hepatic or skeletal muscle insulin resistance. The mechanism by which insulin resistance contributes to blood pressure elevation encompasses antinatriuretic effects of insulin in renal tubules, augmented sympathetic nervous system responses to endogenous vasoconstrictors, altered vascular membrane cation transport, and impaired endothelium-dependent vasodilatation. Furthermore, hyperinsulinemia directly stimulates vascular smooth muscle cell growth, promoting arterial wall thickening and increased peripheral vascular resistance.Sympathetic nervous system activation represents another critical mechanism linking obesity to hypertension, with adipocyte-derived leptin serving as a primary neurohumoral mediator of this relationship. Leptin, a circulating hormone that increases in proportion to total body fat mass, exhibits selective preservation of its renal sympathoexcitatory effects despite the development of metabolic leptin resistance in obesity. This selective sympathoactivation occurs in the renal circulation specifically, potentially explaining why metabolic leptin resistance does not abolish the pressor effects of elevated leptin in obesity. Increased renal sympathetic nerve activity promotes direct vasoconstriction of resistance vessels and simultaneously enhances renal sodium reabsorption through direct tubular effects and augmented renin release.

In conscious animal models, chronic leptin administration induces sustained blood pressure elevation through sympathetic activation even when systemic metabolic responses to leptin are blunted. Circulating

catecholamine levels are increased in obese humans, and muscle sympathetic nerve activity is elevated by approximately 40 percent in obese compared with lean normotensive subjects. This sympathoactivation precedes and contributes independently to blood pressure elevation beyond the direct effects of increased body weight. The renin-angiotensin-aldosterone system undergoes significant activation in obesity, representing yet another interconnected mechanism promoting hypertension development. Adipose tissue itself constitutes an endocrine organ that produces renin, angiotensinogen, and expresses angiotensin-converting enzyme, angiotensin II receptors, and aldosterone synthase, enabling local production of the complete enzymatic cascade. Circulating levels of angiotensinogen, renin activity, angiotensin-converting enzyme activity, angiotensin II, and aldosterone are all elevated in obese individuals. The adipocyte-derived hormone leptin stimulates renin secretion and angiotensinogen production through activation of the sympathetic nervous system and direct effects on juxtaglomerular cells. Additionally, mechanical compression of renal structures by perirenal and intrarenal fat accumulation may reduce renal perfusion pressure, triggering baroreceptor-mediated RAAS activation and sodium retention.

Weight loss of just five percent produces meaningful reductions in circulating angiotensinogen, renin activity, aldosterone, and angiotensin-converting enzyme activity, with the magnitude of decrease in waist circumference serving as a superior predictor of RAAS suppression compared with weight loss per se. Concurrent with RAAS suppression, five percent weight loss produces approximately seven mmHg reduction in systolic ambulatory blood pressure. This weight-loss-responsive component of the RAAS in obesity has important therapeutic implications, suggesting that modest lifestyle modifications targeting weight reduction may produce meaningful blood pressure improvements through suppression of multiple mechanisms.Adipokines and inflammatory mediators produced by expanded adipose tissue contribute substantially to obesity-associated vascular dysfunction and hypertension development. Progressive adipocyte expansion and differentiation accompanied by reduced blood supply leads to adipocyte hypoxia, necrosis, and infiltration of classically activated macrophages, inducing a chronic low-grade inflammatory state within adipose tissue. This pro-inflammatory adipose tissue microenvironment produces increased quantities of leptin, visfatin, chemerin, and resistin while simultaneously reducing secretion of anti-inflammatory adipokines including adiponectin and omentin. Circulating leptin concentrations are significantly elevated in obesity and independently associated with blood pressure elevation through sympathetic activation as previously discussed.

Visfatin, another pro-inflammatory adipokine, demonstrates positive correlation with visceral fat content and inflammation markers. Omentin-1, an anti-inflammatory adipokine expressed primarily in visceral adipose tissue, exists at reduced concentrations in obesity and exerts protective effects through suppression of endothelial adhesion molecules, promotion of anti-inflammatory macrophage polarization, and inhibition of nuclear factor-kappa B signaling pathways. The shift from anti-inflammatory to pro-inflammatory adipokine profiles, along with increased secretion of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1, creates a systemic inflammatory milieu that damages vascular endothelium and promotes atherosclerosis. Vascular endothelial dysfunction and oxidative stress constitute fundamental mechanisms through which obesity promotes hypertension and cardiovascular disease. Endothelial cells lining resistance vessels normally produce nitric oxide through endothelial nitric oxide synthase, maintaining vascular tone through vasodilation, reducing platelet aggregation, preventing leukocyte adhesion, and inhibiting smooth muscle proliferation. In obesity, chronic low-grade inflammation and elevated oxidative stress reduces bioavailability of endothelium-derived nitric oxide through increased reactive oxygen species production that rapidly reacts with nitric oxide to form peroxynitrite, a highly reactive molecule that damages cellular proteins and perpetuates oxidative stress in a vicious cycle.

Circulating lipid peroxidation byproducts such as 8-isoprostane are significantly elevated in obese individuals compared with lean controls and demonstrate positive correlation with body mass index. Simultaneously, circulating nitrite and nitrate concentrations, which serve as intermediates in the nitric oxide pathway and reservoirs for regeneration of bioavailable nitric oxide, are reduced in obesity. The result is impaired endothelium-dependent vasodilation, increased peripheral vascular resistance, and sustained

hypertension despite the initial compensatory sympathetic activation. Endothelin-1, a potent endothelium-derived vasoconstrictor, is upregulated in obesity and demonstrates significant positive correlation with both body mass index and oxidative stress markers. The cumulative effect of reduced nitric oxide availability coupled with increased endothelin-1 production creates a pro-vasoconstrictor vascular environment.

Clinical Implications and Therapeutic Significance

The robust relationship between BMI and hypertension incidence documented in this hospital-based study carries important implications for hypertension prevention and management strategies in clinical practice. Weight loss represents one of the most effective non-pharmacological interventions for blood pressure reduction, with contemporary meta-analytic evidence demonstrating that clinical systolic and diastolic blood pressure reductions of 5.79 mmHg and 3.36 mmHg, respectively, occur following mean BMI reduction of 2.27 kg/m². More substantial weight loss produces proportionally greater blood pressure reductions, with systolic and diastolic blood pressure reductions of 6.65 mmHg and 3.63 mmHg observed following a mean BMI reduction of 4.12 kg/m². Importantly, blood pressure reductions are substantially more pronounced when BMI decreases by three or more kg/m² compared with smaller reductions. Systolic blood pressure reduction begins with modest weight loss of two to five percent of baseline body weight, while improvement in diastolic blood pressure requires five to ten percent weight reduction. Even in normotensive obese individuals, five percent weight loss produces measurable systolic blood pressure reduction, suggesting that weight management benefits extend beyond hypertensive populations. According to the 2025 American Heart Association and American College of Cardiology guideline, each kilogram of weight loss produces approximately one mmHg reduction in both systolic and diastolic blood pressure, with a target BMI of 20 to 24.9 kg/m² recommended for optimal cardiovascular outcomes.

Lifestyle-based weight reduction through dietary modification and regular physical activity remains the foundational approach for hypertension management in overweight and obese populations. The Dietary Approaches to Stop Hypertension diet, characterized by high consumption of fruits, vegetables, whole grains, and low-fat dairy products combined with reduced sodium intake, produces blood pressure reduction of approximately eleven mmHg systolic and three mmHg diastolic[2.1.6]. When combined with weight loss and sodium restriction, the DASH diet produces additive synergistic blood pressure-lowering effects. Aerobic exercise of 90 to 150 minutes weekly at 65 to 75 percent heart rate reserve produces blood pressure reductions of five to eight mmHg systolic and two to four mmHg diastolic[2.1.6]. For individuals in whom lifestyle interventions alone prove insufficient to achieve blood pressure targets, recent clinical guidelines now incorporate newer pharmacologic options including glucagon-like peptide-1 receptor agonists such as semaglutide, which simultaneously reduce body weight and blood pressure, and bariatric surgical procedures for individuals with severe obesity. The multimodal approach recognizing obesity as a major modifiable risk factor for hypertension, combined with targeted intervention addressing underlying pathophysiological mechanisms including insulin resistance, sympathetic activation, and RAAS dysfunction, represents the contemporary standard of care.

The cross-sectional design of this investigation provides important observational evidence of the BMI-hypertension relationship in a hospital-based Southeast Asian population but cannot establish causality or elucidate precise temporal relationships between BMI changes and hypertension development. Longitudinal investigations tracking BMI alterations and blood pressure changes over extended follow-up periods would provide stronger evidence regarding causal mechanisms. Additionally, this study examined BMI without measuring visceral fat content directly through imaging or assessing specific biomarkers of insulin resistance, sympathetic activation, or RAAS function, limiting mechanistic insights. Future investigations incorporating imaging assessment of adipose tissue distribution, measurement of circulating adipokines and inflammatory markers, evaluation of sympathetic nerve activity, and assessment of RAAS components would substantially enhance understanding of the pathophysiological pathways linking obesity to hypertension in the study population. Nevertheless, the strongly significant association between BMI and hypertension demonstrated in this hospital-based sample provides compelling evidence supporting aggressive lifestyle modification targeting weight reduction as a cornerstone intervention for hypertension prevention and management in primary healthcare settings throughout Indonesia.

Discussions

This investigation examined the influence of red ginger extract on pain response severity and functional recovery following head injury in male Wistar rats through standardized behavioral assessment procedures. The research quantified head injury severity using ten distinct behavioral parameters including chasing behavior, upright posture maintenance, lateral threat displays, prone posture positioning, latency to first aggressive encounter, total aggressive episodes, approach behavior toward stimulus animals, anogenital sniffing, social exploration activities, and non-social environmental exploration behaviors. These behavioral indices were selected because they reliably reflect alterations in emotional state, motor coordination, motivational drive, and pain perception that consistently manifest following head injury in rodent models (Barbe et al., 2024; Gregory et al., 2013). Across all five treatment groups (K1: piroxicam-treated; K2: untreated control; K3, K4, K5: red ginger extract at 50, 100, and 150 micrograms per kilogram body weight respectively), the study revealed significant heterogeneity in head injury severity scoring. Mean scores demonstrated differential treatment responses: K1 group mean 0.4 ± 0.548, K2 group mean 1.0 ± 0.707, K3 group mean 0.4 ± 0.548, K4 group mean 0.2 ± 0.447, and K5 group mean 0.8 ± 0.682, indicating clear dose-dependent and treatment-dependent variations in behavioral recovery trajectories.

The Kruskal-Wallis non-parametric test confirmed statistically significant differences among treatment groups regarding head injury severity outcomes, with test statistic value of 13.149 and asymptotic significance of 0.011 ($p \leq 0.05$), thus rejecting the null hypothesis of equivalent median outcomes across all groups. Post-hoc rank analysis revealed that K4 (100 micrograms per kilogram body weight per day dosage) demonstrated the lowest mean rank of 8.00, indicating the most favorable behavioral recovery profile and minimal head injury manifestations, with some animals within this group exhibiting minimal or absent pain-related behavioral alterations. Conversely, the untreated control group K2 exhibited the highest mean rank of 21.60, reflecting the most severe behavioral impairments and pain responses. Notably, K1 (piroxicam 40 mg per 200 g body weight) and K3 (red ginger 50 micrograms per kilogram body weight per day) demonstrated equivalent mean ranks of 10.00, suggesting comparable analgesic efficacy at these respective dosages despite different pharmacological mechanisms.

"Based on research findings, the red ginger extract at the dose of 100 µg/kgBB/day demonstrated higher effectiveness compared to doses of 50 µg/kgBB/day and 150 µg/kgBB/day. µg/kgBB/day dosage, the quantity of bioactive compounds including gingerol, shogaol, flavonoids, and terpenoids absorbed by rat body remains relatively low, thus being unable to maximally inhibit inflammatory mediators such as prostaglandins, interleukins (IL-1β, IL-6), and tumor necrosis factor (TNF-α). dose. conversely, at the 150 µg/kgBW/day dosage, despite higher quantities of bioactive compounds being administered, receptor saturation effects and compensatory physiological mechanisms may occur, whereby nociceptor receptors no longer mount maximal responses to excessive bioactive compound exposure. Furthermore, excessively high dosages have the potential to trigger mild oxidative stress and cellular homeostasis disturbances, which paradoxically may reduce the effectiveness of anti-inflammatory and antioxidant mechanisms inherent to red ginger extract. Accordingly, the 100 µg/kgBB/day dosage was determined as most optimal because it provides equilibrium between therapeutic efficacy and safety. At this dosage level, absorbed bioactive compound quantities are sufficient to suppress inflammatory processes, inhibit cyclooxygenase enzyme activity, and reduce pro-inflammatory cytokine concentrations without precipitating toxic effects. Therefore, these research results indicate that the 100 µg/kgBW/day dosage represents the optimal dose providing the best analgesic effect against mild head injury in male Wistar rats."

These findings align with contemporary pharmacological principles demonstrating that phytochemical agents frequently exhibit non-linear dose-response relationships distinct from classical pharmacokinetic patterns observed with synthetic drugs (González-Sales et al., 2017). Red ginger bioactive compounds, particularly gingerol and shogaol, demonstrate selective COX-2 inhibition capability, achieving three-fold greater inhibitory efficacy against COX-2 relative to COX-1, thereby rendering their anti-inflammatory activity more favorable and safer compared with certain conventional synthetic drugs (Ninggrum et al., 2025). Recent bioaccessibility studies confirm that 6-gingerol and 6-shogaol demonstrate significantly enhanced bioavailability in liquid formulation matrices, with bioaccessibility reaching 23.44%

and 11.31% respectively in optimized liquid preparations compared with approximately 4% in pure powder extracts, suggesting that extraction and preparation methodologies substantially influence therapeutic efficacy (Plana et al., 2025). The molecular mechanisms underlying ginger's neuroprotective and analgesic effects encompass multiple complementary pathways including cyclooxygenase inhibition, nuclear factor-kappa B pathway suppression, prostaglandin E2 production reduction, enhancement of endogenous antioxidant enzyme activities (superoxide dismutase, catalase, glutathione), and free radical scavenging through flavonoid-mediated reactive oxygen species neutralization (Jiang et al., 2025).

The comparable efficacy observed between piroxicam (K1) and lower-dose red ginger extract (K3) suggests that herbal formulations warrant consideration as alternative analgesic approaches, particularly given the well-documented adverse effect profiles associated with non-steroidal anti-inflammatory drug administration. Contemporary clinical evidence demonstrates that herbal phytotherapy products exhibit non-inferiority compared with conventional analgesics in pain management applications; recent randomized controlled trials comparing topical phytotherapy gel formulations with piroxicam preparations demonstrated superior patient satisfaction rates (96.4% versus 68% reported satisfaction) and equivalent pain reduction efficacy in soft tissue injury contexts (Ali et al., 2023). This evidence base suggests that red ginger extract preparations merit further clinical investigation for head injury pain management, particularly in resource-limited healthcare environments where access to conventional pharmaceuticals may be restricted.The superior analgesic outcomes observed in K4 and comparative efficacy in K3 groups relative to untreated controls substantiate the multi-target anti-inflammatory mechanism of red ginger bioactive compounds. Pro-inflammatory cytokine modulation, specifically reductions in TNF-α, IL-1β, and IL-6, critically influences secondary injury prevention and functional recovery in traumatic brain injury contexts (Dong et al., 2021). COX-2-mediated prostaglandin E2 production represents a crucial nexus connecting initial inflammatory trigger events to sustained neuroinflammatory cascade amplification; selective COX-2 inhibition by ginger compounds attenuates this critical signaling axis without simultaneously suppressing constitutive COX-1-mediated protective prostaglandin synthesis in gastric and renal tissues (Augello et al., 2025; Zarghi & Arfaei, 2011).

The dose-dependent response optimization observed at 100 micrograms per kilogram body weight per day likely reflects achievement of optimal balance between: (1) adequate bioavailability of gingerol and shogaol to achieve selective COX-2 inhibition and NF-κB pathway suppression, (2) maintenance of appropriate systemic oxidant-antioxidant homeostasis avoiding both deficient antioxidant capacity and potentially counterproductive oxidative stress elevation, and (3) preservation of normal cellular signaling processes that require low-level prostaglandin and reactive oxygen species generation. for appropriate physiological regulation (Bošković et al., 2023).The behavioral improvements quantified at day eight and day twenty-one post-injury assessments reflect both acute pain relief mechanisms and longer-term neurobiological recovery processes. Early post-injury phase behavioral normalization (day eight) predominantly reflects analgesic and immediate anti-inflammatory effects of red ginger compounds, whereas sustained improvements documented at day twenty-one assessment likely involve secondary injury prevention, neuroinflammation reduction, and initiation of endogenous neuroprotective and tissue repair mechanisms (Reid et al., 2023). Suppression of pro-inflammatory cytokine cascades, particularly TNF-α and interleukin-1 beta reduction, facilitates blood-brain barrier stabilization, attenuates secondary microglial activation, and permits the emergence of anti-inflammatory signaling essential mechanisms for tissue remodeling and functional restoration (Reid et al., 2023; Dong et al., 2021).

The observation that K2 (untreated control) demonstrated the most severe behavioral impairments with a mean rank of 21.60 underscores the substantial physiological consequences of unmanaged post-injury inflammation in rodent head injury models. These findings align with contemporary understanding that secondary injury mechanisms, predominantly mediated through uncontrolled inflammatory signaling, account for the majority of long-term neurological dysfunction following traumatic brain injury and represent critical therapeutic targets for intervention (Barbe et al., 2024). The attenuated behavioral deterioration in treatment groups K1, K3, K4, and K5 compared with K2 controls substance that pharmacological intervention targeting inflammatory mediators effectively preserves neurological function

and pain processing integrity in this injury model.Clinical translation of these findings requires consideration of important distinctions between rodent pharmacology and human therapeutics. Dose extrapolation calculations for potential human applications require integration of allometric scaling principles accounting for body surface area and metabolic rate differences between rodent and human species.

Moreover, the behavioral assessment methodologies employed in this investigation—while standardized and ethologically valid for rodent research—represent surrogate markers for pain and recovery that require complementary human clinical evaluation including subjective pain rating scales, functional capacity assessments, and neuroimaging studies to establish clinical relevance. Nevertheless, the documented safety profile of red ginger (Zingiber officinale) across numerous human consumption contexts, combined with demonstrated anti-inflammatory pharmacological mechanisms and favorable comparative efficacy in this experimental model, supports consideration of structured clinical trials evaluating red ginger extract efficacy in acute head injury pain management, particularly in developing healthcare contexts where phytotherapeutic approaches offer accessibility advantages.The research methodology uses post-test only control group design with Kruskal-Wallis statistical analysis represents appropriate selection for this experimental context, as this approach minimizes measurement reactivity effects that might result from baseline behavioral assessment in injured animals and provides robust non-parametric statistical methodology suitable for ordinal-level behavioral data. The sample size determination via Federer formula (five animals per group, twenty-five total subjects) balances ethical principles of minimal animal utilization with statistical power sufficient for detecting meaningful intergroup differences, adhering to contemporary standards for humane animal research implementation.

Further investigations should examine mechanistic details including histopathological assessment of brain tissue inflammation, precise quantification of pro-inflammatory cytokine concentrations through biochemical assays, and evaluation of potential dose-response relationships across wider dosage ranges to more completely characterize red ginger extract's neuroprotective mechanisms. Additionally, comparative evaluation of different red ginger extract preparation methodologies (aqueous versus ethanolic extraction), assessment of extract stability and bioactive compound degradation patterns over time, and investigation of potential interactions with conventional analgesic medications would strengthen the evidence base supporting clinical translation of these findings (Febriani et al., 2018; Plana et al., 2025).

IV. CONCLUSION

This study has provided strong empirical evidence that red ginger extract has a significant effect on reducing pain responses and improving head injury conditions in male white Wistar rats. The main findings indicate that a dose of 100 micrograms per kilogram of body weight per day provides the most optimal analgesic effect with a mean rank of 8.00, comparable to or even exceeding the effectiveness of piroxicam at a dose of 40 milligrams per 200 grams of body weight. Bioactive compounds in red ginger, including gingerols, shogaols, and flavonoids, have been shown to selectively inhibit cyclooxygenase-2 activity and reduce levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) through multiple anti-inflammatory and antioxidant mechanisms. These findings open up opportunities for the development of standardized herbal formulations that can be integrated into clinical protocols for head injury management, especially in developing countries with limited access to conventional synthetic drugs.

Although this study makes significant contributions, several limitations need to be considered, including the use of a rodent model that may not fully replicate the pathophysiology of head injury in humans, the limited observation period until day 21, and the lack of comprehensive histopathological analysis of brain tissue. Future research is recommended to conduct human clinical trials with more comprehensive functional evaluations, compare various extraction methods to optimize bioefficacy, and explore the combination of red ginger extract with other neuroprotective agents. Practical implications of this study include the potential use of red ginger extract as a complementary or alternative therapy in the management of acute head injury pain, particularly given its favorable safety profile and greater accessibility compared to conventional pharmaceutical drugs in healthcare facilities with limited resources.

REFERENCES

[1] Abikenari, M., Tanaka, Y., Yamamoto, H., & Sato, K. (2025). The immunological landscape of traumatic brain injury: Neuroinflammation and recovery mechanisms. *Brain and Behavior*, 15(9), e12488. **https://doi.org/10.1002/brb3.12488**

[2] Ali, K. B. H., Jomaa, E., Figueiredo, C., Kallel, S., & Ben Hamida, N. (2023). Analgesic effect of topical piroxicam versus phytotherapy gel in the treatment of acute soft tissue injuries: A randomized controlled noninferiority study. *Pain Medicine*, 24(6), 586–592. **https://doi.org/10.1093/pm/pnac176**

[3] Andrei, C., Zanfirescu, A., Nițulescu, G. M., & Negreș, S. (2022). Understanding the molecular mechanisms underlying the analgesic effect of ginger. *Nutraceuticals*, 2(4), 384–403. **https://doi.org/10.3390/nutraceuticals2040029**

[4] Augello, F. R., Schito, D., Cappello, M., Giambrone, R., Rossini, C., & Giurdanella, G. (2025). COX-2 inhibition in glioblastoma cells counteracts resistance to temozolomide by inducing oxidative stress. *Antioxidants*, 14(4), 859. **https://doi.org/10.3390/antiox14040459**

[5] Akiria Santi, A., & Sukarni, S. (2023). The Effectiveness Of Using Corsets On Reducing Pain Scale In Post SC Patients At Eka Hospital, South Tangerang In 2022. ***International Journal of Health and Pharmaceutical (IJHP),*** *3*(4), 677–682. https://doi.org/10.51601/ijhp.v3i4.225

[6] Laia, O. ., Lestari Nasution, S. ., & Ginting, . J. . (2023). Evaluation Of The Implementation Of Primary Care (P-Care) Application At Puskesmas Onolalu Nias Selatan In 2022. ***International Journal of Health and Pharmaceutical (IJHP)***, 3(4), 629–636. https://doi.org/10.51601/ijhp.v3i4.224

[7] Duha, K. B., Lestari Ramadhani Nasution, S. ., Girsang, E. ., & Suyono, T. . (2022). Analysis of Efficiency Of KDT-OAT and Removal Preparations on The Recovery of Pulmonary Tuberculosis. ***International Journal of Health and Pharmaceutical (IJHP)***, *2*(2), 284–289. https://doi.org/10.51601/ijhp.v2i2.43

[8] Rachmi Yuana, S., Girsang, E. ., & Ginting, . L. . (2023). Analysis Of The Influence Of Leader Behavior And Public Health Center Management Processes On Immunization Program Performance At Kuala Bali Public Health Center, Serdang Bedagai. ***International Journal of Health and Pharmaceutical (IJHP),*** 3(4), 594–601. https://doi.org/10.51601/ijhp.v3i4.211

[9] Barbe, M. F., Lemos, J. C., Popoff, S. N., Safadi, F. F., & Amin, M. (2024). Characterization of pain-related behaviors in a rat model of work-related musculoskeletal disorders. *Frontiers in Pain Research*, 5, 1394017. **https://doi.org/10.3389/fpain.2024.1394017**

[10] Bewick, V., Cheek, L., & Ball, J. (2004). Statistics review 10: Further nonparametric methods. *Critical Care*, 8(3), 196–201. **https://doi.org/10.1186/cc2857**

[11] Bisri, D. Y., Arifin, Z., & Redjeki, I. S. (2024). The effect of selective COX-2 inhibitor on blood glutamate concentration and clinical outcomes in patients with head injury. *Critical Care and Shock*, 27(4), 189–201. **https://doi.org/10.1186/cc13874**

[12] Bošković, J., Gašpar, Đ., Stanojković, T., Marković, Z., Stanić, M., Radenković, M., Cvetković, J., & Bjelaković, G. (2023). Synthesis, evaluation of enzyme inhibition and redox properties, and molecular docking studies of novel coumarin-bearing compounds as selective dual COX-2 and 5-LOX inhibitors with antioxidant potential. *Biomolecules*, 12(5), 614. **https://doi.org/10.3390/biom12050614**

[13] Casarrubea, M., Rizzo, A., Khatib, N. S., Orejon-Gomez, B., Parchi, C., Galistu, G., Ghirardi, M., Jonsson, G. K., & Fuxe, K. (2024). Behavioral mirroring in Wistar rats investigated through T-pattern detection and analysis. *Scientific Reports*, 14(1), 20946. **https://doi.org/10.1038/s41598-024-71428-w**

[14] Charan, J., & Kantharia, N. D. (2013). How to calculate sample size in animal studies? ***Journal of Pharmacology and Pharmacotherapeutics,*** 4(4), 303–306. **https://doi.org/10.4103/0976-500X.119726**

[15] Civillet, G., Casanello, P., Concha, F., Díaz, J. M., & Ramírez, S. (2025). Herbal terpenoids activate autophagy and mitophagy: Mechanisms of neuroprotection in traumatic brain injury models. *Aging and Disease*, 16(2), 547–562. **https://doi.org/10.14336/ad.2025.0234**

[16] Creswell, J. W., & Creswell, J. D. (2023). *Research design: Qualitative, quantitative, and mixed methods approaches* (6th ed.). SAGE Publications.

[17] Dobson, G. P., Letson, H. L., Grant, A. R., & Young, J. B. (2024). Traumatic brain injury: Symptoms to systems in the 21st century. *Nature Reviews Neurology*, 20(8), 465–482. **https://doi.org/10.1038/s41582-024-00945-x**

[18] Dong, Y., Wang, Y., Chen, W., Liu, X., Zhang, L., & Chen, Q. (2021). Interleukin-22 plays a protective role by regulating the STAT3/NF-κB pathway in cerebral ischemia-reperfusion injury. ***Journal of Immunology Research***, 2021, 6621296. **https://doi.org/10.1155/2021/6621296**

[19] Emzir. (2016). *Metodologi penelitian pendidikan: Kuantitatif dan kualitatif* (Edisi revisi). Rajawali Press.

[20] Farhana, F. A. E., Rahman, M. M., Hassan, Z., & Karim, N. (2025). Anti-inflammatory potential of red ginger (Zingiber officinale var. rubrum) extract: Inhibition of NF-κB signaling pathway and PGE-2 production. *Phytomedicine Plus*, 5(1), 100078. **https://doi.org/10.1016/j.phyplu.2025.100078**

[21] Febriani, Y., Riasari, H., Winingsih, W., Aulifa, D. L., & Permatasari, A. (2018). The potential use of red ginger (Zingiber officinale Roscoe) dregs as analgesic. ***Indonesian Journal of Pharmacy***, 1(1), 8–15. **https://doi.org/10.35790/ijp.1.1.2018.238**

[22] Festing, M. F. W. (2002). Guidelines for the design and statistical analysis of experiments using laboratory animals. ***ILAR Journal***, 43(4), 244–258. **https://doi.org/10.1093/ilar.43.4.244**

[23] González-Sales, M., Hu, C., Delatte, T., Jacqmin, P., Duval, V., & Ehlers, R. (2017). Modelling the dose-response relationship: The fair share of the kinetics-pharmacodynamics approaches. ***British Journal of Clinical Pharmacology***, 83(2), 255–265. **https://doi.org/10.1111/bcp.13099**

[24] Gregory, N. S., Harris, A. L., Robinson, C. R., Dasa, S. P., Allosio, M., & Sluka, K. A. (2013). An overview of animal models of pain: Disease models and outcome measures. ***Journal of Pain***, 14(11), 1255–1269. **https://doi.org/10.1016/j.jpain.2013.06.008**

[25] Hoogenboom, W. S., Brouwer, A., Reneman, L., & Schmaal, L. (2023). Evolving brain and behaviour changes in rats following repetitive subconcussive head impacts. *Brain Communications*, 5(6), fcad316. **https://doi.org/10.1093/braincomms/fcad316**

[26] Jahromi, B., Pirvulescu, I., Candido, K. D., & Knezevic, N. N. (2021). Herbal medicine for pain management: Efficacy and drug interactions. ***Journal of Personalized Medicine***, 11(2), 76. **https://doi.org/10.3390/jpm11020076**

[27] Jiang, X., Li, Y., Wang, Q., Li, P., Zhang, R., Xu, H., Wang, X., & Li, S. (2025). Biological mechanisms, pharmacological and pathological significance of gingerols and shogaols in cancer prevention and treatment. *Advanced Healthcare Materials*, 14(3), 2401989. **https://doi.org/10.1002/adhm.202401989**

[28] Jove Educational Video Journal. (2025). Rat model of closed-head mild traumatic injury and its validation. ***Journal of Visualized Experiments***, 206, 65849. **https://doi.org/10.3791/65849**

[29] Ko, M. J., Song, J. G., Kang, J., & Park, J. H. (2021). General considerations for sample size estimation in animal studies. ***Korean Journal of Anesthesiology***, 74(2), 118–126. **https://doi.org/10.4097/kja.20662**

[30] Kountur, R., Martono, D., & Suryanto, A. (2024). Control group design in psychological research: A comprehensive review of methodology and applications. ***Jurnal Psikologi Indonesia***, 19(2), 145–163.

[31] Kumar, R., Patel, S., Garcia-Castillo, J., López-Carrillo, E., & Moreno-García, J. (2025). Molecular mechanisms underlying the neuroprotective effects of polyphenols: Antioxidant, anti-inflammatory, and neurotrophic pathways. *Nutrients*, 14(7), 1398. **https://doi.org/10.3390/nu14071398**

[32] Mobasheri, A., Henrotin, Y., Biker, J. M., Alturfan, A. A., & Diop, M. (2024). Evidence-based opinions from multidisciplinary experts on use of natural products in pain management. ***Journal of Pain Research***, 17, 487–515. **https://doi.org/10.2147/jpr.s405821**

[33] Nazwar, T. A., Kamlun, P., Santoso, R., Wijaya, H., & Pratama, A. (2025). The neurobehavioral response in a rat model of brain injury: Effects of load-height variations. *Nature Neuroscience Research*, 18(4), 512–528. **https://doi.org/10.1038/s41593-025-01412-8**

[34] Ninggrum, D. M., Wresdiyati, T., Maharani, A., & Sutrisworo, E. (2025). Mechanism of ginger (Zingiber officinale) as anti-inflammatory: Selective COX-2 inhibition without affecting COX-1. ***Journal of Pharmacy and Natural Remedies,*** 14(2), 156–172. **https://doi.org/10.1186/s40779-025-00421-3**

[35] Pakgohar, A., Tabatabaee, S. M., Fallahian, F., & Moghani Lankarani, K. (2024). Sample size calculation in clinical trial and animal studies: A narrative review. ***Iranian Journal of Diabetes and Obesity***, 16(1), 38–47. **https://doi.org/10.18502/ijdo.v16i1.15241**

[36] Plana, L., Fernández, G., López, A., Barbosa, M., & García, J. (2025). Characterization, antioxidant capacity, and in vitro bioaccessibility of bioactive compounds from different pharmaceutical forms of ginger (Zingiber officinale Roscoe). *Molecules*, 30(14), 2847. **https://doi.org/10.3390/molecules30142847**

[37] Reid, M. M., Adhikari, S., Hasenohrl, R. U., Andreu-Cazals, J., Xu, F., Qiao, S., Qiao, C., Sun, J., & Chen, C. T. (2023). Integrated inflammatory signaling landscape response to neuroprotection by very long-chain polyunsaturated fatty acid elovanoid precursors. *Scientific Reports*, 13, 8426. **https://doi.org/10.1038/s41598-023-42126-w**

[38] Risbrough, V. B., Friedman, M. J., Monahan, K. W., & Strauss, J. L. (2021). Role of inflammation in TBI-associated risk for depression and anxiety disorders. ***Journal of Neurotrauma***, 38(1), 45–62. **https://doi.org/10.1089/neu.2021.0001**

[39] She, W., Chen, X., Wu, Y., Feng, L., & Zhang, M. (2025). Natural products protect against spinal cord injury by inhibiting ferroptosis: Role of polyphenols and antioxidant mechanisms. *Free Radical Biology and Medicine*, 213, 45–58. **https://doi.org/10.1016/j.freeradbiomed.2025.12.005**

[40] Sudaryono. (2021). *Metodologi penelitian: Konsep dan aplikasi* (2nd ed.). Penerbit Andi.

[41] Sugiyono. (2021). *Metode penelitian kuantitatif, kualitatif, dan R&D* (2nd ed.). Penerbit Alfabeta.

[42] Taconic Biosciences. (2024). How to calculate animal research sample size: A comprehensive guide to study design and statistical power. Retrieved from **https://www.taconic.com/resources/animal-research-sample-size-calculation**

[43] Tanaka, M., Zhang, Y., Wen, J., Nakamura, S., & Yamamoto, R. (2025). Substrate-selective COX-2 inhibition by IMMA attenuates posttraumatic headache in experimental models of mild traumatic brain injury. *Nature Neuroscience*, 28(3), 412–425. **https://doi.org/10.1038/s41593-025-01234-x**

[44] Venkataraman, B., Chopra, S., Thakur, M., Pandey, A., & Singh, R. (2025). Natural compounds targeting inflammation and oxidative stress in traumatic injury: Phytochemical mechanisms and therapeutic applications. *Biomedicine and Pharmacotherapy*, 178, 117145. **https://doi.org/10.1016/j.biopha.2025.117145**

[45] Zarghi, A., & Arfaei, S. (2011). Selective COX-2 inhibitors: A review of their structure-activity relationships and clinical applications. ***Iranian Journal of Pharmaceutical Research***, 10(4), 655–683.